| Ranolazine: a review of its use in chronic stable angina pectoris. | |
| | |
MedLine Citation:
|
PMID: 19016575 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Extended-release ranolazine (ranolazine ER) [Ranexa] is a piperazine derivative with a novel mechanism of action that was recently approved in the EU for use as add-on therapy in patients with stable angina pectoris. Ranolazine ER achieves its antianginal effect without affecting heart rate or blood pressure (BP) to a clinically significant extent. Results of well designed, placebo-controlled, short-term studies demonstrate that add-on therapy with ranolazine ER in patients with chronic stable angina improves exercise performance, and reduces anginal frequency and nitroglycerin use. Although longer-term therapy with ranolazine ER did not reduce the incidence of major cardiovascular events in patients with non-ST-elevation acute coronary syndromes, it did reduce the incidence of recurrent ischaemia. Ranolazine ER is a generally well tolerated antianginal agent. Although it is associated with modest dose-related increases in the corrected QT (QTc) interval, ranolazine ER does not appear to be associated with an excess of arrhythmias. Thus, ranolazine ER is a useful new option for patients with chronic stable angina whose symptoms are not controlled with first-line antianginal therapy or who do not tolerate first-line antianginal agents. |
| | |
Authors:
|
Gillian M Keating |
Related Documents
:
|
7457415 - Improved exercise performance in persons with stable angina pectoris receiving diltiazem. 3073525 - The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patie... 2834115 - Improvement of treadmill capacity and collateral circulation as a result of exercise wi... 1937985 - Exercise cardiovascular responses to gallopamil in ischemic heart disease. 9650735 - Heritability of running economy: a study made on twin brothers. 2457765 - Enhanced postischemic atp repletion by pharmacological inhibition of nucleoside washout... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 68 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-11-21 Completed Date: 2009-02-27 Revised Date: 2011-09-16 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 2483-503 Citation Subset: IM |
Affiliation:
|
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetanilides*
/
pharmacology,
therapeutic use Angina Pectoris / drug therapy* Cardiovascular Agents* / pharmacology, therapeutic use Chronic Disease Delayed-Action Preparations Humans Piperazines* / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Acetanilides; 0/Cardiovascular Agents; 0/Delayed-Action Preparations; 0/Piperazines; 110445-25-5/ranolazine |
| Comments/Corrections | |
Erratum In:
|
Drugs. 2011 Jul 9;71(10):1332 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a m...
Next Document: Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejec...